Corex opens new clinical trial logistics hub in Ukraine

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/Naruedom)
(Image: Getty/Naruedom)

Related tags: Clinical trial, Clinical data management, Supply chain, Logistics, Clinical trial protocol

Corex will expand to additional markets after opening a new clinical trial logistics hub in Ukraine.

The new strategic Kyiv, Ukraine-based location comes after Corex experienced operational growth as a clinical trials logistics company in the country. The opening of this center, according to Corex, reinforces its commitment to the region’s growing clinical trial market.

“We are convinced that this latest addition to Corex international infrastructure will serve as a stepping stone to both strengthening the existing operations and opening new markets in the coming months,”​ said Rostislav Kachan, head of Corex Ukraine in a statement.

The logistics hub features temperature-controlled storage capabilities and walk-in refrigerators and has been inspected by the Ukrainian State Administration on Medicinal products.

Kachan said the company has “hit the ground running” ​and is already started managing existing clients at its new facility.

Expanding footprint in expanding region

In 2014, Synergy Research Group revealed that 108 of the 155 trials approved​ in Ukraine in the first half of 2014 were multinational, multi-center clinical trials. At the time, the contract research organizations (CROs) Quintiles (now Iqvia), PPD, and PSI AG conducted a majority of these trials.

Ukraine has an approximate population of 45m and follows EU directives and guidelines for clinical trial legislation and data quality. The company stated that clinical trial data from Ukraine is corroborated by both US Food and Drug Administration (FDA) and European Medicines Agency (EMA) inspections.

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more